Esperion Announces Positive Phase 2 Clinical Trial Results for ETC-1002Esperion Therapeutics, a privately held biotechnology company in Plymouth, Monday announced positive results from a Phase 2 clinical trial for its potential cholesterol buster, ETC-1002.
Metabolic Solutions Receives $1.1 Million NIH GrantMetabolic Solutions Development Co. LLC announced it has received a $1.1 million multi-year Small Business Technology Transfer Program grant from the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health. The company will use the money to develop its drug candidate for fatty liver disease.
NephRx Corp. Starts Human Trial Of Kidney Transplant Assist Drug
Karmanos Cancer Center Gets New Prostate Drug